66 results
8-K
EX-1.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable … as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
;
the potential benefits of our arrangements with Gilead Sciences, Inc., Sanofi S.A. and Seagen Inc. (now a part of Pfizer Inc.);
the timing of and our ability … Form W-8BEN, IRS Form W-8BEN-E or other appropriate form, certifying the Non-U.S. Holder’s entitlement to benefits under the treaty. Such form must
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
, protein degradation, antibody-drug conjugation, and DACs may potentially address a broad range of diseases;
the potential benefits of our … , certifying the Non-U.S. Holder’s entitlement to benefits under the treaty. Such form must be provided prior to the payment of dividends and must be updated
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
and findings from Nurix’s preclinical studies and clinical trials; the potential benefits of and Nurix’s expectations with respect to its strategic
8-K
EX-99.1
3efbul6
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
EX-99.1
0bn728lf
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.2
fc63q4mm
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
fpagtu 41cvk6d1v3mtu
13 Nov 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
3ekzezjzf95zoext
12 Oct 23
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:03pm
8-K
3in5w6mdtepiev8o9p
7 Sep 23
Entry into a Material Definitive Agreement
7:02am
424B5
ap5dlir93of3
8 Jul 22
Prospectus supplement for primary offering
4:10pm
424B5
bko99ki eo
8 Jul 22
Prospectus supplement for primary offering
4:09pm